7 September 2021 - Luspatercept (Reblozyl) is used to treat patients with certain transfusion-dependent anaemias.

The TGA has approved the use of luspatercept for:

• The treatment of adult patients with transfusion-dependent anaemia (requiring 2 or more red blood cell units over 8 weeks) due to very low, low and intermediate-risk myelodysplastic syndromes with ring sideroblasts
• The treatment of adult patients with transfusion-dependent anaemia associated with beta thalassaemia

Read TGA Australian prescription medicine decision summary